GlobeNewswire PharmaOriginal article
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
Data ReadoutpositivePlinabulinDocetaxelPembrolizumabPositive
AI Analysis
Summary
BeyondSpring reported positive long-term survival data from ASCO 2026 for plinabulin combined with docetaxel and pembrolizumab in metastatic NSCLC patients who progressed on first-line immune checkpoint inhibitor therapy.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Long-term survival benefit demonstrated for plinabulin/docetaxel and pembrolizumab in metastatic NSCLC following progression on first-line ICI therapy
Importance:7/10
Sentiment:
0.70
ASCO 2026oncologyNSCLCimmunotherapysurvival benefitsecond-line therapy
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 14, 2026 9:15 PM